NextBio and Genophen Form Partnership Aimed at Applying Genomics to
Personalized Disease Prevention and Wellness
SANTA CLARA, Calif., April 2, 2013
SANTA CLARA, Calif., April 2, 2013 /PRNewswire/ -- NextBio and Genophen
announced today a partnership aimed at furthering the adoption of genomics for
disease prevention and wellness. The partnership enables Genophen to interpret
full genome sequencing data from individuals through the use of the NextBio
Clinical platform and to combine this data with a person's environmental,
behavioral and clinical factors to create a uniquely tailored disease
prevention and wellness plan for its individual members.
"Genophen is the first company to take lifestyle factors in synergy with
genetic information derived from full genome sequencing to create a
personalized health risk assessment and a set of recommendations for each
individual," said Hossein Fakhrai-Rad, PhD, Co-Founder, Chief Executive
Officer, and President of Genophen. "NextBio's vast and comprehensive
repository of curated genomic and clinical data from the public domain adds
depth to our analysis. This partnership with NextBio Clinical enables us to
efficiently analyze and interpret whole genome data."
"Genophen's aim is to make the dream of personalized medicine a tangible
reality," said Saeid Akhtari, President and CEO of NextBio. "Our partnership
allows NextBio to take a first step towards the use of genomics for wellness
and disease prevention, one of the ultimate goals of modern medicine."
Genophen has developed a healthcare software platform which assesses an
individual's disease risks comprehensively and provides a personalized and
actionable set of recommendations to keep individuals healthy, for longer. The
risk assessment engine calculates health risks based on genetic, behavioral,
environmental, and medical factors for multi-factorial diseases and it is
targeted at disease prevention. The platform provides a deeply personalized
set of recommendations that even specifies an individual's recommended food
and physical activity based on their unique health conditions and genetic
profile. The Genophen platform is a two-centric model, designed as a clinical
tool for physicians with primary focus around delivery of care, and as a
patient centric model to engage each individual in their own health.
NextBio provides a state of the art scientific platform to aggregate and
interpret large quantities of molecular and other life sciences data for
research and clinical applications. NextBio's platform integrates data from
multiple repositories and diverse technologies by means of a unique
correlation engine, which pre-computes billions of significant connections
between disparate public and proprietary clinical and experimental data. This
feature enables interpretation of an individual's molecular data. It also
provides translational researchers the ability to look across the clinical and
molecular data of entire populations for clinical trial stratification and
selection, hypotheses generation, and biomarker discovery. NextBio Clinical,
which recently passed an independent HIPAA audit, is designed for seamless
integration with existing clinical and research systems. Backed by highly
scalable, Big Data technology, it is capable of analyzing petabytes of data.
NextBio's platform is delivered as a SaaS (Software as a Service) solution
resulting in quick deployment and rapid return on investment.
Today, NextBio is used by researchers and clinicians in over 50 top commercial
and academic institutions including the National Institute of Health, The
University of Southern California, Sanford-Burnham Medical Research Institute,
Sanofi, Pfizer, Novartis, Celgene, Eli Lilly, Genzyme, Johnson & Johnson,
Merck, Regeneron, GlaxosmithKline, Harvard Medical School, Scripps Research
Institute, Stanford University, University of California at Berkeley, Takeda
and many others. To learn more about NextBio, please visit our website at
Contact: Saeid Akhtari, President and CEO, NextBio, email@example.com; Joan
Kureczka, Kureczka/Martin Associates, +1-415-821-2413, +1-415-690-0210
Press spacebar to pause and continue. Press esc to stop.